|Outcome||Comparison||Number of trials (n)||RRR (95% CI)|
|*ICSs = inhaled corticosteroids; SABAs = short acting β2 agonists; LABAs = long acting β2 agonists; LPMs/RAs = leukotriene pathway modifiers/receptor antagonists. Other abbreviations defined in glossary; RRR and CI calculated from data in article.|
|†Calculated using a random effects model.|
|Rate of exacerbations||ICSs v placebo or SABAs||11 (9418)||54% (38 to 66)†|
|LABAs v placebo||9 (2854)||25% (12 to 36)|
|ICSs plus LABAs v ICSs||7 (3886)||26% (9 to 39)|
|ICSs plus LABAs v doubled dosage of ICSs||10 (5680)||14% (4 to 24)|
|LPMs/RAs v placebo||7 (4375)||41% (29 to 51)|
|ICSs plus anti-IgE antibodies v ICSs||3 (1388)||45% (34 to 55)|
Review: long term use of common medications for asthma reduces exacerbations in adults
This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of EBN.
View free sample issue >>
EBN Online Journal Club
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.